Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
Oncoimmunology ; 12(1): 2244330, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37577144

RESUMEN

Malignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes. While many of these immune evasion networks include checkpoint proteins, small molecular weight compounds, such as the amino acid L-kynurenine (LKU), could also substantially contribute to the suppression of anti-cancer immunity. However, the biochemical mechanisms underlying the suppressive effects of LKU on T-cells remain unclear. Here, we report for the first time that LKU suppresses T cell function as an aryl hydrocarbon receptor (AhR) ligand. The presence of LKU in T cells is associated with AhR activation, which results in competition between AhR and hypoxia-inducible factor 1 alpha (HIF-1α) for the AhR nuclear translocator, ARNT, leading to T cell exhaustion. The expression of indoleamine 2,3-dioxygenase 1 (IDO1, the enzyme that leads to LKU generation) is induced by the TGF-ß-Smad-3 pathway. We also show that IDO-negative cancers utilize an alternative route for LKU production via the endogenous inflammatory mediator, the high mobility group box 1 (HMGB-1)-interferon-gamma (IFN-γ) axis. In addition, other IDO-negative tumors (like T-cell lymphomas) trigger IDO1 activation in eosinophils present in the tumor microenvironment (TME). These mechanisms suppress cytotoxic T cell function, and thus support the tumor immune evasion machinery.


Asunto(s)
Quinurenina , Neoplasias , Humanos , Quinurenina/metabolismo , Quinurenina/farmacología , Evasión Inmune , Transducción de Señal , Linfocitos T , Microambiente Tumoral
2.
Oncotarget ; 6(30): 28678-92, 2015 Oct 06.
Artículo en Inglés | MEDLINE | ID: mdl-26384306

RESUMEN

Correction of human myeloid cell function is crucial for the prevention of inflammatory and allergic reactions as well as leukaemia progression. Caffeine, a naturally occurring food component, is known to display anti-inflammatory effects which have previously been ascribed largely to its inhibitory actions on phosphodiesterase. However, more recent studies suggest an additional role in affecting the activity of the mammalian target of rapamycin (mTOR), a master regulator of myeloid cell translational pathways, although detailed molecular events underlying its mode of action have not been elucidated. Here, we report the cellular uptake of caffeine, without metabolisation, by healthy and malignant hematopoietic myeloid cells including monocytes, basophils and primary acute myeloid leukaemia mononuclear blasts. Unmodified caffeine downregulated mTOR signalling, which affected glycolysis and the release of pro-inflammatory/pro-angiogenic cytokines as well as other inflammatory mediators. In monocytes, the effects of caffeine were potentiated by its ability to inhibit xanthine oxidase, an enzyme which plays a central role in human purine catabolism by generating uric acid. In basophils, caffeine also increased intracellular cyclic adenosine monophosphate (cAMP) levels which further enhanced its inhibitory action on mTOR. These results demonstrate an important mode of pharmacological action of caffeine with potentially wide-ranging therapeutic impact for treating non-infectious disorders of the human immune system, where it could be applied directly to inflammatory cells.


Asunto(s)
Cafeína/farmacología , Linaje de la Célula , Células Mieloides/efectos de los fármacos , Serina-Treonina Quinasas TOR/metabolismo , Xantina Oxidasa/metabolismo , Proteínas Angiogénicas/metabolismo , Basófilos/efectos de los fármacos , Basófilos/enzimología , Cafeína/metabolismo , Línea Celular Tumoral , Citocinas/metabolismo , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Glucólisis/efectos de los fármacos , Humanos , Mediadores de Inflamación/metabolismo , Leucemia Mieloide Aguda/enzimología , Leucemia Mieloide Aguda/patología , Monocitos/efectos de los fármacos , Monocitos/enzimología , Células Mieloides/enzimología , Células Mieloides/patología , Transducción de Señal/efectos de los fármacos
3.
Sci Rep ; 4: 6307, 2014 Sep 09.
Artículo en Inglés | MEDLINE | ID: mdl-25200751

RESUMEN

Xanthine oxidase (XOD) is an enzyme which plays a central role in purine catabolism by converting hypoxanthine into xanthine and then further into uric acid. Here we report that XOD is activated in THP-1 human myeloid cells in response to pro-inflammatory and growth factor stimulation. This effect occurred following stimulation of THP-1 cells with ligands of plasma membrane associated TLRs 2 and 4, endosomal TLRs 7 and 8 as well as stem cell growth factor (SCF). Hypoxia-inducible factor 1 (HIF-1) and activator protein 1 (AP-1) transcription complexes were found to be responsible for XOD upregulation. Importantly, the mammalian target of rapamycin (mTOR), a major myeloid cell translation regulator, was also found to be essential for XOD activation. Specific inhibition of XOD by allopurinol and sodium tungstate led to an increase in intracellular AMP levels triggering downregulation of mTOR activation by phosphorylation of its T2446 residue. Taken together, our results demonstrate for the first time that XOD is not only activated by pro-inflammatory stimuli or SCF but also plays an important role in maintaining mTOR-dependent translational control during the biological responses of human myeloid cells.


Asunto(s)
Inflamación/inmunología , Células Mieloides/fisiología , Serina-Treonina Quinasas TOR/metabolismo , Xantina Oxidasa/metabolismo , Alopurinol/farmacología , Animales , Línea Celular Tumoral , Regulación hacia Abajo , Activación Enzimática , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Lipopolisacáridos , Hígado/metabolismo , Células MCF-7 , Masculino , Ratones , Peptidoglicano , Fosfatidilinositol 3-Quinasas/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosforilación , Interferencia de ARN , ARN Interferente Pequeño , Factor de Células Madre/metabolismo , Receptor Toll-Like 2/metabolismo , Receptor Toll-Like 4/metabolismo , Receptor Toll-Like 7/metabolismo , Receptor Toll-Like 8/metabolismo , Factor de Transcripción AP-1/antagonistas & inhibidores , Factor de Transcripción AP-1/metabolismo , Compuestos de Tungsteno/farmacología , Ácido Úrico/análisis , Xantina Oxidasa/antagonistas & inhibidores , Xantina Oxidasa/biosíntesis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...